Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.21.1
Stockholders' Equity (Tables)
 9 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Schedule of aggregate offering price
Three months ended   Avg price
per share		     Number of
Shares		     Gross
Proceeds
(in millions)		     Offering
Expenses
(in millions)		     Net
Proceeds
(in millions)		  
September 30, 2020   $ 8.09       416,221     $ 3.4     $ 0.1     $ 3.3  
December 31, 2020   $ 8.93       2,296,023     $ 20.5     $ 0.4     $ 20.1  
March 31, 2021   $ 14.99       2,082,148     $ 31.2     $ 0.5     $ 30.7  
Total   $ 11.49       4,794,392     $ 55.1     $ 1.0     $ 54.1  
Schedule of Black-Scholes option pricing model with weighted average assumptions
    Nine Months
Ended
March 31,
2021		  
Exercise price   $ 7.72 – 17.61  
Expected term (years)   4.00 – 5.00  
Risk-free interest rate   0.25% – 0.78%  
Volatility   67 – 68%  
Dividend yield   0%
Weighted Average Grant Date Fair Value of Options granted during the period   $ 5.05  
Schedule of aggregate offering price
    Three Months Ended
March 31,		     Nine Months Ended
March 31,		  
    2021     2020     2021     2020  
Research and Development   $ 1,011     $ 929     $ 2,953     $ 2,675  
General and Administrative     980       874       3,131       2,433  
Total   $ 1,991     $ 1,803     $ 6,084     $ 5,108  
Schedule of unrecognized stock-based compensation expense and weighted-average years
    As of March 31, 2021  
    Unrecognized
stock-based
compensation		     Weighted-
average years
to be recognized		  
Options   $ 2,820       2.21  
Restricted stock awards/units   $ 9,064       2.29